Evidence map›Paper›PMID 31629857›Full record

ArticleExperimental neurology2020

Adenosine 2A receptor inhibition protects phrenic motor neurons from cell death induced by protein synthesis inhibition.

Yasin B Seven, Alec K Simon, Elaheh Sajjadi, Amanda Zwick, Irawan Satriotomo, Gordon S Mitchell

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Experimental neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05377424 (Acute Adenosine Receptor Antagonism to Promote Breathing Plasticity in ALS), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05377424 phase1 / phase2active not recruitingnot on this mapstarted 2022, after this paper: background citation

Acute Adenosine Receptor Antagonism to Promote Breathing Plasticity in ALS

TypeinterventionalSponsorUniversity of FloridaRan2022 to 2026Enrolled40ConditionsALSArmsConsume 20mg of istradefylline, Low Oxygen therapy, Placebo counterpart to the istradefylline drug, SHAM counterpart to low oxygen therapy.
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Adenosine AFrontiers in neuroscience · 2021
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Yasin B SevenCenter for Respiratory Research and Rehabilitation, Department of Physical Therapy and McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA.
Alec K SimonCenter for Respiratory Research and Rehabilitation, Department of Physical Therapy and McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA.
Elaheh SajjadiCenter for Respiratory Research and Rehabilitation, Department of Physical Therapy and McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA.
Amanda ZwickCenter for Respiratory Research and Rehabilitation, Department of Physical Therapy and McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA.
Irawan SatriotomoCenter for Respiratory Research and Rehabilitation, Department of Physical Therapy and McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA.
Gordon S MitchellCenter for Respiratory Research and Rehabilitation, Department of Physical Therapy and McKnight Brain Institute, University of Florida, Gainesville, FL 32610, USA. Electronic address: gsmitche@phhp.ufl.edu.
University of Florida · US

Funding

Respiratory Plasticity and Spinal Cord InjuryR01HL069064 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI MITCHELL, GORDON S. · 2014 to 2017
$1.5M
NHLBI NIH HHS R01 HL069064
6 · The paper itself

Abstract

Respiratory motor neuron survival is critical for maintenance of adequate ventilation and airway clearance, preventing dependence to mechanical ventilation and respiratory tract infections. Phrenic motor neurons are highly vulnerable in rodent models of motor neuron disease versus accessory inspiratory motor pools (e.g. intercostals, scalenus). Thus, strategies that promote phrenic motor neuron survival when faced with disease and/or toxic insults are needed to help preserve breathing ability, airway defense and ventilator independence. Adenosine 2A receptors (A2A) are emerging as a potential target to promote neuroprotection, although their activation can have both beneficial and pathogenic effects. Since the role of A2A receptors in the phrenic motor neuron survival/death is not known, we tested the hypothesis that A2A receptor antagonism promotes phrenic motor neuron survival and preserves diaphragm function when faced with toxic, neurodegenerative insults that lead to phrenic motor neuron death. We utilized a novel neurotoxic model of respiratory motor neuron death recently developed in our laboratory: intrapleural injections of cholera toxin B subunit (CtB) conjugated to the ribosomal toxin, saporin (CtB-Saporin). We demonstrate that intrapleural CtB-Saporin causes: 1) profound phrenic motor neuron death (~5% survival); 2) ~7-fold increase in phrenic motor neuron A2A receptor expression prior to cell death; and 3) diaphragm muscle paralysis (inactive in most rats; ~7% residual diaphragm EMG amplitude during room air breathing). The A2A receptor antagonist istradefylline given after CtB-Saporin: 1) reduced phrenic motor neuron death (~20% survival) and 2) preserved diaphragm EMG activity (~46%). Thus, A2A receptors contribute to neurotoxic phrenic motor neuron death, an effect mitigated by A2A receptor antagonism.

Indexed as

Adenosine A2 Receptor AntagonistsAnimalsApoptosisCholera ToxinDiaphragmMaleMotor NeuronsPhrenic NervePurinesRatsRats, Sprague-DawleySaporinsAdenosine A2 Receptor AntagonistsCholera Toxincholera toxin B-saporin conjugateistradefyllinePurinesSaporinsA2A receptorAdenosineADORA2AApoptosisNeuroprotectionp38Phrenic motor neuron survival

Identifiers

PMID31629857
PMCPMC7336167
OpenAlexW2981144515

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.